more commonly known as H. pylori. The bacteria accounted for an estimated 810,000 cancer cases in 2018, the most recent year ...

H. pylori bacteria are able to colonize and replicate in the human stomach and/or the human duodenum. This is primarily owing to their ability to persist in the acid environment of the stomach ...

Although many H. pylori infections are asymptomatic and can be harmless, the adaptations of this bacteria mean that it’s very capable of evading the human immune system and can be difficult to ...

The authors conclude that infection with cagA-positive strains of H. pylori could be a strong predisposing factor for the development of gastric adenocarcinoma.

Several Twitter users on Thursday, November 25, took to the micro-blogging site to narrate their experiences with bacteria Helicobacter pylori (H. Pylori). The users observed that H. Pylori seems ...

Zon100 is more than just an herbal remedy—it represents a breakthrough in the fight against H pylori and can potentially ...

This is a bacterium Helicobacter pylori or H.pylori. These bacteria are commonly present in the stomach and create inflammation by destroying the mucus lining (inner lining which helps to ...

These findings are suggestive but not diagnostic of H. pylori infection. Magnifying endoscopy can reveal more precisely the abnormal mucosal patterns in an H. pylori-infected stomach; however ...

Helicobacter pylori (H. pylori) infections affect an estimated 50% to 60% of the population in India and constitute a significant public health challenge. This bacterial infection, which often ...

pylori) bacteria, though antibiotics are still necessary for complete eradication. “In animals, we’ve seen that some probiotics can suppress H. pylori,” he said, noting one study that ...

This study aimed to evaluate the relative risk of H. pylori infection and CGC in Asian countries. Relevant studies examining H. pylori and CGC were searched in PubMed, Embase, and Web of Science ...

TenNor Therapeutics, a clinical-stage company dedicated to developing novel therapies to address unmet needs in infectious diseases, announced today the successful completion of a phase III clinical ...